When: Confirmed close above $226.93 (Sept 28 high) on >6M shares for 2 consecutive sessions

Then: Incremental add

When: Daily close below $210.26 on >6M shares (50 SMA failure)

Then: Trim 25% of position, retain core

When: Daily close below $207 on >5M shares

Then: Further 25% reduction, approaching Underweight sizing

When: Closing basis below $207

Then: Thesis invalidation — exit half

When: Rally into $225-230 range

Then: Do not trim — negative expected value ahead of binary catalyst

HOLD at 75% of typical position size; trim 20-25% into $225-$230 rallies; do not add at current $217 or $195-$201; hard stop at $207 if 50 SMA fails on volume

• Forward PE of 23.4x is at high end of DHR's historical range; consensus estimates can be revised lower on integration stumbles, bioprocessing softness, FX shifts, or healthcare capex pullback
• Leverage elevated for a defensive compounder; M&A accretion scenario assumes "flawless integration in a 96 percent no-cut macro" which is a bull case, not base case
• Sentiment silence is a non-signal — absence of retail euphoria is not evidence of institutional accumulation; also means thinner liquidity and less bid support on downside
• Macro "priced in" means low bar for disappointment, not high bar for relief; in "higher for longer" regime, path of least resistance for premium-multiple compounders is multiple compression
• MACD histogram expanded negative from -0.54 to -0.63 (worsening); price closed below 10 EMA and below VWMA; ATR is 6.58 (less than 2 days of normal range to stop)
• 50 SMA at 210.26 is 3.2% below current price; aggressive analyst's stop at 207 creates 3.2-4.6% failure zone
• Pullback zone at $195-$201 contains 200 SMA at 200.73 and Bollinger lower band at 201.14 — levels that would indicate uptrend has cracked, not a buying opportunity
• Q3 earnings is single-event dependency; bioprocessing disappointment, conservative Cepheid guide, higher integration costs, or FX headwind of ~200bps could cause gap down in stock with no observable buy-side support
• Conservative position is 75% of typical size vs. aggressive position which implicitly recommends heavier exposure than currently on books
• Asymmetries work both ways — in current environment, prudent posture is reduce exposure rather than increase it

→ vs aggressive: Forward PE of 23.4x is not a fact but a forecast; treating consensus estimates as a valuation floor ignores risk of downward revision from integration challenges, bioprocessing softness, FX headwinds, or healthcare capex pullback

→ vs aggressive: Framing leverage concerns as "distressed credit" is a rhetorical move — elevated leverage for a defensive compounder in hostile macro is a legitimate risk even if not distressed, and 52-66% EPS accretion assumes flawless execution which is bull case not base case

→ vs aggressive: Interpreting sentiment silence as institutional accumulation is fabricating a narrative from a data void — absence of retail euphoria is not evidence of institutional buying; it means we don't know what smart money is doing and liquidity is thinner

→ vs aggressive: "Priced in" means low bar for further disappointment, not high bar for relief; in "higher for longer" regime, premium-multiple compounders face multiple compression, not expansion — the asymmetric move could be down

→ vs aggressive: MACD histogram expanded negative (worsening, not stabilizing); ATR of 6.58 means aggressive analyst's stop at $207 creates a 3.2-4.6% failure zone that is less than 2 days of normal trading range — not a generous risk buffer

→ vs aggressive: $195-$201 zone contains 200 SMA at 200.73 and Bollinger lower band at 201.14 — if reached, uptrend has cracked and entire thesis should be reassessed, not treated as a buying opportunity

→ vs aggressive: Entire upside thesis to $230-$240 depends on Q3 earnings beat — single-event dependency that risk managers should avoid; no buy-side support means gap down risk on any miss

HOLD current position size through Q3 earnings; add 25-33% on daily close above $218.50 with volume above 5M shares (stop at $210); add incrementally on confirmed breakout above $226.93 with volume above 6M shares; trim 25% on daily close below $210 with volume above 6M shares; further reduce on close below $207 with volume confirmation

• Q3 earnings catalyst window is mid-to-late October; Cepheid respiratory ramp is November through February
• Upside trigger 1: Daily close above $218.50 with volume above 5 million shares warrants adding 25-33% to position with stop at $210
• Upside trigger 2: Confirmed breakout above $226.93 with volume above 6 million shares warrants incremental add, stop at $210
• Downside trigger 1: Daily close below $210 on volume above 6 million shares (50 SMA failure) warrants trimming 25% of position
• Downside trigger 2: Close below $207 on volume confirms breakdown and warrants further reduction
• Do not add at $217; do not trim preemptively ahead of catalyst window
• Conservative analyst's 75% size cap is premature de-risking on a structural quality compounder that has held the 50 SMA and 200 SMA throughout
• Aggressive analyst's quiet accumulation inference is not evidence but storytelling; single-event Q3 earnings dependency creates binary risk
• DHR defensive characteristics (beta 0.80) should cushion multiple compression relative to higher-beta growth names but do not fully insulate from higher-for-longer regime
• After Q3 earnings, position can be sized toward 100% of typical on confirmed breakout if constructive, or cap at 75% if earnings disappoint

→ vs aggressive: The 'quiet accumulation' inference from sentiment silence is data void filled with bullish narrative, not evidence; also the entire $230 target and 3-to-1 reward-to-risk framing is single-event dependent on Q3 beat, creating binary risk rather than asymmetric setup

→ vs conservative: Treating 38.8x TTM PE as anchor when underlying earnings are transitional is selective framing; the $195-201 zone is not automatically thesis-broken but a level where successful re-rating probability improves; trim proposal at $225-230 has negative expected value given quality profile asymmetry